AbbVie (incl. ImmunoGen, Capstan)

A pill that removes the survival shield from leukaemia cells, enabling chemotherapy-free, time-limited treatment for CLL.

Mirvetuximab soravtansine (Elahere) is the first ADC for ovarian cancer, for tumours with high folate receptor alpha.

Telisotuzumab vedotin (Emrelis) is the first c-MET-directed ADC, approved in 2025 for lung cancer with high c-MET protein.

Telisotuzumab adizutecan is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly.

Budigalimab is an experimental investigational agent whose form is not stated in the registry from AbbVie in phase 3 trials for hepatocellular carcinoma, non-small-cell lung cancer and bladder & urothelial cancer, with its target not yet stated publicly.

Livmoniplimab is an experimental investigational agent whose form is not stated in the registry from AbbVie in phase 3 trials for hepatocellular carcinoma, non-small-cell lung cancer and bladder & urothelial cancer, with its target not yet stated publicly.

ABBV-706 is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.

Navitoclax is an experimental small-molecule drug from AbbVie in phase 3 trials for myeloproliferative neoplasms, with its target not yet stated publicly.

Dronabinol is synthetic THC in a capsule, approved in 1985 for chemotherapy nausea and vomiting that other antiemetics have failed to control, and later for appetite loss in AIDS; it sits well behind the 5-HT3 and NK1 antagonists in today's guidelines.

The other endothelin blocker. Adding it to chemotherapy for advanced prostate cancer changed nothing, and the trial was stopped for futility.

Depatuxizumab mafodotin carried a cell-killing payload to glioblastomas with extra copies of the EGFR gene. It caused serious eye problems and, in the phase 3 INTELLANCE-1 trial, did not help patients live longer, so development stopped in 2019.

Epcoritamab is an under-the-skin injection that pulls T cells onto lymphoma cells; it is approved for relapsed large B-cell and follicular lymphoma, and moving toward first line.

The pill that ended chemotherapy for most CLL. It blocks the survival signal B cells depend on, and it was the first drug to beat chemoimmunotherapy in nearly every CLL setting.

An Indian-discovered antibody that grips two targets on myeloma cells at once while pulling in T cells to kill them, licensed to AbbVie in 2025 in the biggest deal yet for an Indian cancer drug.

Leuprolide is the injectable that shuts off testosterone production, the foundation of hormone therapy for prostate cancer since the 1980s; it is also used for ovarian suppression in premenopausal breast cancer.

Pivekimab sunirine is an antibody-drug conjugate against CD123, approved in 2026 for blastic plasmacytoid dendritic cell neoplasm as the second targeted drug for this rare cancer.

Rovalpituzumab tesirine (Rova-T) was the first drug against DLL3 in small-cell lung cancer. AbbVie bought it for $5.8B and abandoned it after two failed phase 3 trials. The target later worked with a different weapon.

Veliparib is a PARP inhibitor that AbbVie tested with chemotherapy in breast cancer. It added nothing to carboplatin before surgery (BrighTNess) and lengthened progression-free but not overall survival with carboplatin and paclitaxel in inherited BRCA advanced disease (BROCADE3), so it was never licensed.